
West Pharmaceutical Services company profile
$416.42+1.24%Close 13 Nov 2026
About West Pharmaceutical Services
West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs and healthcare products. Its Proprietary Products segment offers elastomer and primary containment components such as stoppers, seals, syringe and cartridge components, vials, plungers, drug delivery and self-injection devices, integrated systems and analytical lab services, primarily for biologic, generic and pharmaceutical drug customers. Its Contract-Manufactured Products segment designs, manufactures and assembles complex devices and customer-owned components for pharmaceutical, diagnostic and medical device customers. The company has manufacturing facilities in North and South America, Europe and Asia, and sells through its own sales force and distribution network. Sales outside the U.S. accounted for 56.7% of consolidated net sales in 2025.
A summary of the business section of the company's latest annual report, filed 17 Feb 2026.
Company facts
| Ticker | WST · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Supplies |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 105770 |
|---|
| Latest annual report | 10-K, filed 17 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Douglas A. Michels | Director | 44.6K · < 1% | Grant or award, 4 May 2026 |
|---|
| Thomas W. Hofmann | Director | 43.7K · < 1% | Grant or award, 6 May 2025 |
|---|
| Mark A. Buthman | Director | 43.5K · < 1% | Grant or award, 4 May 2026 |
|---|
| William F. Feehery | Director | 30.7K · < 1% | Grant or award, 4 May 2026 |
|---|
| Myla P. Lai-Goldman | Director | 18.6K · < 1% | Grant or award, 4 May 2026 |
|---|
| Robert W. McMahon | SVP & Chief Financial Officer | 14.6K · < 1% | Option exercise, 11 Aug 2026 |
|---|
| Paolo Pucci | Director | 10.0K · < 1% | Grant or award, 4 May 2026 |
|---|
| Deborah L. V. Keller | Director | 9.7K · < 1% | Grant or award, 4 May 2026 |
|---|
| Robert F. Friel | Director | 3.6K · < 1% | Grant or award, 4 May 2026 |
|---|
| Molly E. Joseph | Director | 3.6K · < 1% | Grant or award, 4 May 2026 |
|---|
| Shane A. Campbell | SVP, Proprietary Segment | 3.1K · < 1% | Shares withheld for tax, 12 May 2026 |
|---|
| Stephen H. Lockhart | Director | 2.7K · < 1% | Grant or award, 4 May 2026 |
|---|
| Janet B. Haugen | Director | 456 · < 1% | Grant or award, 4 May 2026 |
|---|
| Annette F. Favorite | Sr. VP & Chief HR Officer | — | Sale under a 10b5-1 plan, 15 Sep 2026 |
|---|
| Winters Chad | VP, Chief Accounting Officer | — | Open-market sale, 27 Apr 2026 |
|---|
| Poussot Rodolphe Jean | SVP, Strategy & Corporate Dev | — | Shares withheld for tax, 20 Feb 2026 |
|---|
| Witherspoon Charles | VP & Treasurer | — | Shares withheld for tax, 20 Feb 2026 |
|---|
| Eric M. Green | President, CEO and Board Chair · Director | — | Option exercise, 18 Feb 2026 |
|---|
| Bernard J. Birkett | Sr VP, Chief Financial Officer | — | Shares withheld for tax, 18 Feb 2025 |
|---|
| Kimberly B. MacKay | SVP, GC & Corporate Secretary | — | Shares withheld for tax, 18 Feb 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
WST in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.